Sugi Predict

Sugi Predict / Compounds / SCHEMBL4364436

SCHEMBL4364436

SCHEMBL4364436

C/C=C/C=C/C(=O)Oc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.48
▸ HTR1A P08908 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ ZDHHC2 Q9UIJ5 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HPGD P15428 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HTT P42858 2/20 0.40
▸ ATM Q13315 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ ELANE P08246 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27149 1.00 MAOB (0.48) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL27987849 0.98 MAOB (0.47) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL20565176 0.90 MAOB (0.54) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL17138211 0.87 KMT2A (0.47) MAOBHTR1AKMT2AMEN1KDM4E
SCHEMBL17138213 0.87 KMT2A (0.47) MAOBHTR1AKMT2AMEN1KDM4E
SCHEMBL574099 0.86 KMT2A (0.50) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL574100 0.86 KMT2A (0.50) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL11212354 0.84 MAOB (0.50) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL11212343 0.84 MAOB (0.50) MAOBHTR1AKMT2AZDHHC2MEN1
SCHEMBL7100110 0.84 HSD17B10 (0.50) KMT2AMEN1HPGDHSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4430037-B1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-10-29 — — EP disclosed
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORP (US) 2025-09-11 — — US disclosed
EP-4573090-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2025-06-25 — — EP disclosed
US-20250122186-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-04-17 — — US disclosed
EP-3715421-B1 RESIN COMPOSITION, MELT-MOLDING MATERIAL, MULTILAYER STRUCTURE, AND LIQUID PACKAGING MATERIAL MITSUBISHI CHEM CORP (JP) 2025-03-26 — — EP disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 — — WO disclosed
US-20250064809-A1 Inhibitors of Mutant RET Kinases for use in Treating Cancer STEMLINE THERAPEUTICS, INC. (US) 2025-02-27 — — US disclosed
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 — — US disclosed
US-12180211-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2024-12-31 — — US disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 — — US disclosed
CN-101222916-A Phenol derivatives and their use to modulate PKB activity IMP INNOVATIONS LTD (GB) 2008-07-16 — — CN disclosed
CN-101190933-A 6-O-methylerythromycin A crystal form III LINGFENG WANG (CN) 2008-06-04 — — CN disclosed
CN-1754884-A Crystal form ii of clarithromycin ABBOTT LAB (US) 2006-04-05 — — CN disclosed
CN-1216892-C Crystalline form I of clarithromycin ABBOTT LAB (US) 2005-08-31 — — CN disclosed
US-20050119260-A1 Inhibitors of cellular necrosis BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-06-02 — — US disclosed
CN-1161360-C Tetrazole-containing rapamycin analogs with reduced half-lives ���Ͽع����޹�˾ 2004-08-11 — — CN disclosed
CN-1271361-A Tetrazole-containing rapamycin analogs with shortened half-lives ABBOTT LAB (US) 2000-10-25 — — CN disclosed
CN-1261281-A Peptide parathyroid hormone analogs RHONE POULENC RORER PHARMA (US) 2000-07-26 — — CN disclosed
CN-1229411-A Crystalline form I of clarithromycin ABBOTT LAB (US) 1999-09-22 — — CN disclosed
US-5795372-A CARBOXYLIC ACID, AROMATIC HYDROXY COMPOUND HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1998-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180211-B2 Compounds, compositions and methods BAX, CASP3, CASP8 MAOB 3313/4885HTR1A 3809/4885KMT2A 4832/4885
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 MAOB 2416/4885HTR1A 4610/4885KMT2A 1686/4885
US-20050119260-A1 Inhibitors of cellular necrosis TNF, AIFM1, BAD MAOB 529/4885HTR1A 3852/4885KMT2A 4809/4885
US-20250064809-A1 Inhibitors of Mutant RET Kinases for use in Treating Cancer RET, BRAF, HRAS MAOB 3968/4885HTR1A 4370/4885KMT2A 860/4885
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS PTPN5, PTPN2, PTPRJ MAOB 4620/4885HTR1A 4651/4885KMT2A 1435/4885
US-20250122186-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK2, RIPK3 MAOB 3498/4885HTR1A 3432/4885KMT2A 3551/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 MAOB 2416/4885HTR1A 4610/4885KMT2A 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.